Table 1.
Study cohort characteristics
| CD4 < 200 (N = 17) | CD4 > 200 (N = 17) | P value | |
|---|---|---|---|
| Mean age (years) | 50 ± 9 | 47 ± 7 | 0.2619 |
| Weight (kg) | 54.71 ± 9.71 | 58.18 ± 8.63 | 0.1895 |
| BMI (kg/m2) | 21.19 ± 3.52 | 21.69 ± 2.92 | 0.4691 |
| Time on ART (years) | 7 ± 3 | 9 ± 2 | 0.0951 |
| Gender, N (%) | |||
| Male | 7 (41.2) | 8 (47.1) | > 0.9999 |
| Female | 10 (50.0) | 9 (52.9) | |
| Ethnicity, N (%) | |||
| Han | 4 (23.5) | 4 (23.5) | > 0.9999 |
| Other minorities | 13 (58.8) | 13 (76.5) | |
| Acquisition of HIV, N (%) | |||
| Injection drug use | 3 (17.6) | 1 (5.9) | 0.7309 |
| Sexual route | 12 (70.6) | 14 (82.3) | |
| Unknown | 2 (11.8) | 2 (11.8) | |
| T cells (cells/μL) | |||
| CD4+ T cell counts before ART | 159 ± 143 | 210 ± 149 | 0.1425 |
| CD3+ T cell counts | 642 ± 263 | 764 ± 178 | 0.0518 |
| CD4+ T cell counts | 149 ± 38 | 266 ± 57 | < 0.0001* |
| CD8+ T cell counts | 448 ± 233 | 454 ± 171 | 0.4902 |
| CD4/CD8 ratio | 0.40 ± 0.20 | 0.72 ± 0.45 | 0.0033* |
| Nadir CD4+ T cell counts | 144 ± 37 | 239 ± 36 | < 0.0001* |
| ART regimens, N (%) | |||
| NRTI + NNRTI | 13 (76.5) | 17 (100) | 0.1026 |
| NRTI + PI | 4 (23.5) | 0 (0) | |
| 3TC + AZT + EFV | 4 (23.5) | 5 (29.4) | 0.1404 |
| 3TC + AZT + NVP | 3 (17.6) | 6 (35.3) | |
| 3TC + TDF + EFV | 5 (29.4) | 5 (29.4) | |
| 3TC + AZT + LPV | 2 (11.8) | 0 (0) | |
| 3TC + TDF + NVP | 1 (5.9) | 1 (5.9) | |
| TDF + AZT + LPV | 1 (5.9) | 0 (0) | |
| 3TC + LPV | 1 (5.9) | 0 (0) | |
Data are presented as Mean ± SD unless otherwise indicated. P values were calculated using Mann–Whitney test. Red marked lines represent P < 0.05. BMI body mass index, HIV human immunodeficiency virus, ART antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, 3TC lamivudine, AZT zidovudine, EFV efavurebz, NVP nevirapine, TDF tenofovir, LPV lopinavir
*P < 0.05